The optic nerve consists of more than one million nerve fibers and its function is to carry visual messages to the brain. Optic nerve disorders cause damage to the nerve due to factors ranging from infection to trauma. Damage to an optic nerve can cause vision loss, reduction in visual acuity, loss or reduction in color vision, pupil response abnormality and others. Optic nerve disorders drugs are used for the treatment and mitigation of optic nerve disorders.
The growing incidences of optic nerve disorders are the demand drivers of the optic nerve disorders drugs market. Optic neuritis affects adults between the ages of 25 to 45 years. The incidence rate of optic neuritis is 5 out of 100000 each year. Almost 3 million Americans suffer from glaucoma resulting in more than 120,000 blind patients and accounting for 9% to 12% of all cases of blindness. According to the World Health Organization, Glaucoma is the second leading cause of blindness in the world after cataracts. The large economic burden of optic nerve disorders is another driver of the optic nerve disorders drugs market. Glaucoma alone accounts for over 10 million physician’s visits each year in the U.S. and costs over $1.5 billion annually in terms of lost income social security benefits,, and health care expenditures.
The growing risk factors such as autoimmune diseases, diabetes and bacterial infection are the driving factors of optic nerve disorders. Growing screening rates and the advent of magnetic resonance spectroscopy and healthcare penetration is another driver of the optic nerve disorders drugs market. Exposure to toxins and drugs such as, Ethambutol, Amiodarone, Tobacco, Ethylene glycol, and others, is driving the optic nerve disorders drugs market.
Factors restraining the optic nerve disorders drugs market include poor efficacy and efficiency, high cost and lack of ophthalmology hospitals in developing nations. Lack of awareness and the low efficacy and efficiency of drugs coupled with the lack of curative treatment for some optic nerve disorders such as glaucoma is restraining the optic nerve disorders drugs market.
Request Free Sample Report@ https://www.factmr.com/connectus/sample?flag=S&rep_id=2689
Optic Nerve Disorders Drugs Market: Segmentation
The optic nerve disorders drugs market is segmented on the basis of indication, drug class, end user and region.
Based on indication, the global optic nerve disorders drugs market is segmented into:
- Ischemic Optic Neuropathies
- Optic Neuritis and Perineuritis
- Compressive Optic Neuropathies
- Intrinsic Neoplasms
- Hereditary Optic Neuropathies
- Inflammatory Optic Neuropathies
- Infectious Optic Neuropathies
- Toxic and Nutritional Optic Neuropathies
- Traumatic Optic Neuropathy
- Optic Disc Drusen
- Anomalous Optic Neuropathy
Based on drug class, the global optic nerve disorders drugs market is segmented into:
- Nerve Tonics and Multivitamin
- Hyperosmotic Agents
- Carbonic Anhydrase Inhibitors
- Beta-blockers and Alpha-adrenergic Agonists
Based on end user, the global optic nerve disorders drugs market is segmented into:
- Home Settings
Request/View TOC@ https://www.factmr.com/connectus/sample?flag=T&rep_id=2689
Optic Nerve Disorders Drugs Market: Overview
Based on regions, the global optic nerve disorders drugs market is classified into North America, Latin America, Europe, CIS & Russia, Japan, Asia-Pacific excluding Japan (APEJ), and the Middle East & Africa (MEA). North America is expected to account for the largest share in the global optic nerve disorders drugs market owing to large incomes and excellent reimbursements. The excellent support of the US government programs such as Prescription assistance programs, Resources for macular degeneration and glaucoma, Medicare, Medicaid, Social Security and others is driving a large optic nerve disorders market.
China and India are expected to drive the lion’s share in the optic nerve disorders drugs market in the Asia-Pacific excluding Japan (APEJ) region. The inclusion of glaucoma in national health programs in developing countries is driving a large market for optic nerve disorders.
The European optic nerve disorders drugs market is expected to be led by Germany, France and the UK. The Middle Eastern and African optic nerve disorders drugs market is anticipated to be dominated by the Gulf nations of Saudi Arabia, UAE, Kuwait and Qatar. The poor per capita income of African countries is likely to restrict the growth of the optic nerve disorders drugs market in this region.
Optic Nerve Disorders Drugs Market: Key Players
Some of the major players in the global optic nerve disorders drugs market are SANTHERA PHARMACEUTICALS, Quark, Novartis AG, Allergan plc, Merck & Co., Stealth BioTherapeutics Inc., Takeda Pharmaceutical Company, and others.
This market study is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain. The study provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The study also maps the qualitative impact of various market factors on market segments and geographies.
The market study covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes:
- North America
- Latin America
- Rest of LATAM
- EU – 4 (Germany, France, Italy, Spain)
- BENELUX (Belgium, Netherlands, Luxemburg)
- NORDIC (Norway, Denmark, Iceland, Sweden)
- Eastern Europe (Poland, Ukraine, Czech Rep., etc.)
- Rest of Europe
- CIS & Russia
- Greater China
- ASEAN Countries
- Rest of APEJ
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of MEA
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.